Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Reducing death and disability from stroke: the role of governmental advocacy.
Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.
Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States.
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):527-9.
View in:
PubMed
subject areas
Antineoplastic Agents
Clinical Trials, Phase I as Topic
Dose-Response Relationship, Drug
Drug-Related Side Effects and Adverse Reactions
Humans
Maximum Tolerated Dose
Research Design
authors with profiles
Mark J. Ratain